reports
- Wedbush Research
- David Nierengarten
- Dennis Pak
- Martin Fan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted ...
- Wedbush Research
PEGA PEGASYSTEMS INC.
KURA KURA ONCOLOGY INC.
ISR ISORAY
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
ORIC ORIC PHARMACEUTICALS
SNOW SNOWFLAKE INC. CLASS A
TNGX TANGO THERAPEUTICS
GLUE INC
JANX MONTE ROSA THERAPEUTICS INC
MLTX JANUX THERAPEUTICS INC
CRBP MOONLAKE IMMUNOTHERAPEUTICS
BCAX CORBUS PHARMACEUTICALS HOLDINGS INC.
BICARA THERAPEUTICS INC.
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Wedbush Research
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CRM SALESFORCE.COM INC.
AXTI AXT INC.
CDR CD PROJEKT S.A.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
MSFT MICROSOFT CORPORATION
SMCI SUPER MICRO COMPUTER
ORIC INC.
AI ORIC PHARMACEUTICALS
STX C3.AI
GFS SEAGATE TECHNOLOGY HLDGS PLC
S GLOBALFOUNDRIES INC
JANX SENTINELONE INC
PEPG JANUX THERAPEUTICS INC
DBD PEPGEN INC
DIEBOLD NIXDORF INCORPORATED
- David Nierengarten
- Dennis Pak
- Martin Fan
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financi...
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash and investments expected to fund current operating plan into the second half of 2027 and through anticipated primary endpoint readout from first ORIC-944 Phase 3 registrational trial in prostate cancer SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE...
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary ...
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still o...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 4, 2025, at 12:50 p.m. ETGoldman Sachs 46th Annual Global Healthcare Conference – Participating in...
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of O...
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor i...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
NVCR NOVOCURE LTD.
FATE FATE THERAPEUTICS INC
MRSN MERSANA THERAPEUTICS
ISR ISORAY
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ACET ADICET BIO INC
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
GLUE MONTE ROSA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX BICARA THERAPEUTICS INC.
Farmers & Merchants Bancorp (FMCB) Increases Cash Dividend for the 60t...
Farmers & Merchants Bancorp (FMCB) Increases Cash Dividend for the 60th Consecutive Year LODI, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Farmers & Merchants Bancorp (OTCQX: FMCB) (the “Company” or “FMCB”), the parent company of Farmers & Merchants Bank of Central California (the “Bank” or “F&M Bank”), the Board of Directors declared a mid-year cash dividend of $9.30 per share, an increase of 5.7% over the $8.80 per share paid in July of 2024. The cash dividend is payable on July 1, 2025, to shareholders of record on June 10, 2025. Net income over the trailing twelve months was $88.7 millio...
Team, Inc. Reports First Quarter 2025 Results
Team, Inc. Reports First Quarter 2025 Results SUGAR LAND, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights: Generated first quarter 2025 revenue of $198.7 million and a gross margin of 23.8%.Reported a net loss of $29.7 million, inclusive of a $1...
Team, Inc. Announces Timing of First Quarter Earnings Release and Conf...
Team, Inc. Announces Timing of First Quarter Earnings Release and Conference Call SUGAR LAND, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today announced that it will issue its first quarter 2025 earnings release on Monday, May 12, 2025 after the close of trading on the New York Stock Exchange. TEAM will host a conference call to discuss its finan...
Clene Reports First Quarter 2025 Financial Results and Recent Operatin...
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyelination and ne...
- Wedbush Research
RHP RYMAN HOSPITALITY PROPERTIES INC.
PEB PEBBLEBROOK HOTEL TRUST
NBIX NEUROCRINE BIOSCIENCES INC.
APLE APPLE HOSPITALITY REIT INC
HST HOST HOTELS & RESORTS INC.
PK PARK HOTELS & RESORTS INC.
ANAB ANAPTYSBIO INC.
HEAR TURTLE BEACH CORP.
ORIC ORIC PHARMACEUTICALS
PLTR PALANTIR TECHNOLOGIES
PAY PAYMENTUS HLDGS INC
GETY GETTY IMAGES HOLDINGS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and...
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NS...
- David Nierengarten
- Dennis Pak
- Martin Fan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2025 (the “Grant Date”), ORIC granted a total of 32,400 non-qualified stock options and 5,200 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2025. These inducement grants were granted pu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.